Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children

ILLUMINATE-B Workgroup

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry